Brief: Personalis Says Analysis From Tracerx Study Reveals More Sensitive And Earlier Ctdna Detection In Lung Cancer Patients By Personalis' Mrd Technology
21/10/2023 17:34
Oct 21 (Reuters) - Personalis Inc PSNL.O :
* ANALYSIS FROM TRACERX STUDY REVEALS MORE SENSITIVE AND
EARLIER
CTDNA DETECTION IN LUNG CANCER PATIENTS BY PERSONALIS' MRD
TECHNOLOGY
Source text for Eikon: ID:nBw9PPT3Na
Further company coverage: PSNL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Personalis
See all newsBrief: Personalis - Announces Commercial Launch Of Real-Time Variant Tracker In Next Personal Mrd Test
U.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
Personalis slips as BTIG downgrades, sees no rival bid for Tempus deal
Brief: Personalis Receives New Task Order Under U.S. Veterans Affairs Contract For VA MVP
Personalis, Inc. reports results for the quarter ended June 30 - Earnings Summary